TABLE 1.
Characteristics and treatment information of 20 patients given tigecycline
| Patient | Infection type(s)a | Pathogen(s) isolated (sample type)b | Comorbidity | Concomitant drugs | Renal failure (undergoing hemodialysis) | Hepatic impairment (Child-Pugh class) | Dosage (mg) | Duration of treatment (days) | Hemorrhage (site) | Blood transfusion | Treatment outcome |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Pneumonia, cIAIs | A. baumannii (sputum), Enterococcus faecium (ascites) | Hepatitis B, post-liver transplantation | Cyclosporine/voriconazole/caspofungin/entecavir/piperacillin-tazobactam | No | Yes (A) | 50 q8h | 21 | Yes (airway) | No | Completion |
| 2 | cIAIs | Negative | Diabetes | Imipenem-cilastatin/cefoperazone-sulbactam/fluconazole/aspirin/low-molecular-weight heparin | Yes (Yes) | No | 50 q12h | 27 | Yes (alimentary tract) | Yes | Completion |
| 3 | Pneumonia | A. baumannii (sputum) | Diabetes | Cefoperazone -sulbactam/caspofungin/linezolid | Yes (No) | No | 50 q12h | 14 | No | No | Completion |
| 4 | Pneumonia | A. baumannii, KPCs (sputum) | Diabetes | Voriconazole/piperacillin-tazobactam/linezolid | Yes (Yes) | No | 50 q12h | 14 | No | No | Death |
| 5 | Bacteremia, pneumonia | A. baumannii (blood, sputum) | Trauma, amputation | Cefoperazone-sulbactam/fluconazole | No | No | 50 q12h | 15 | Yes (surgical wound、alimentary tract) | Yes | Completion |
| 6 | Pneumonia | A. baumannii (sputum) | Subarachnoid hemorrhage, hypertension, diabetes, hepatitis C | Fluconazole/clopidogrel | No | No | 50 q12h | 14 | No | No | Completion |
| 7 | Pneumonia | A. baumannii (sputum) | Hypertension | Ceftazidime/voriconazole | Yes (Yes) | No | 50 q12h | 24 | Yes (incision wound) | Yes | Completion |
| 8 | Pneumonia | A. baumannii (sputum) | Dermatitis medicaments, hypertension | Fluconazole | No | No | 50 q12h | 14 | No | No | Death |
| 9 | Bacteremia | ESBLs-K. pneumoniae, E. faecium (blood) | Portal thrombosis | Imipenem-cilastatin/amikacin/piperacillin-tazobactam/low-molecular-weight heparin | No | No | 50 q12h | 14 | No | No | Completion |
| 10 | Pneumonia | A. baumannii (sputum) | Lung cancer | Voriconazole/vancomycin/imipenem-cilastatin/cefoperazone-sulbactam | No | No | 50 q12h | 15 | No | No | Death |
| 11 | cIAIs | Negative | Gastric cancer | Piperacillin-tazobactam/fluconazole | No | No | 50 q12h | 8 | Yes (alimentary tract) | Yes | Completion |
| 12 | Pneumonia, cSSSIs | A. baumannii (sputum), E. coli (wound secretion) | Trauma | Cefoperazone-sulbactam/vancomycin/micafungin/levofloxacin | No | No | 50 q12h | 14 | No | Yes | Death |
| 13 | Pneumonia, septic shock | None | Diabetes, rheumatoid arthritis | Low-molecular-weight heparin/imipenem-cilastatin | No | Yes (B) | 50 q12h | 7 | No | No | Death |
| 14 | Pneumonia | Negative | Myelodysplastic syndrome, posthematopoietic stem cell transplantation | Piperacillin-tazobactam/cyclosporine/caspofungin/fluconazole/methylprednisolone | No | No | 50 q12h | 21 | No | No | Completion |
| 15 | Pneumonia | A. baumannii (sputum) | Percutaneous aortic valve replacement, COPDc | Ceftazidime/clopidogrel | No | No | 100 q12h | 9 | Yes (airway, subcutaneous) | Yes | Death |
| 16 | Bacteremia | None | Hematopoietic function exhaustion | Piperacillin-tazobactam | No | Yes (C) | 50 q12h | 6 | No | Yes | Completion |
| 17 | Bacteremia, pneumonia | MRSA, A. baumannii (blood、sputum) | Trauma: paraplegia, hepatitis B | Ceftazidime/clopidogrel/voriconazole/cefoperazone-sulbactam | No | Yes (B) | 50 q12h | 14 | No | No | Completion |
| 18 | cIAIs | Negative | Acute lymphoblastic leukemia, hypertension | Itraconazole/imipenem-cilastatin | No | No | 50 q12h | 8 | No | Yes | Completion |
| 19 | Pneumonia | MRSA (sputum) | COPD, hypertension | Methylprednisolone/imipenem-cilastatin | No | No | 50 q12h | 10 | No | No | Death |
| 20 | Pneumonia | A. baumannii (sputum) | A amikacin/cefoperazone-sulbactam/cefoselis/low-molecular-weight heparin | No | No | 50 q12h | 24 | No | No | Completion |
a
cIAIs, complicated intra-abdominal infections; cSSSIs, complicated skin and skin structure infections.
b
KPCs, K. pneumoniae carbapenemases; ESBLs, extended-spectrum β-lactamases; MRSA, methicillin-resistant S. aureus.
c
COPD, chronic obstructive pulmonary disease.